Incorporating the Next Generation of Immunotherapies Into the Treatment of Multiple Myeloma
{{output}}
Immunotherapies have recently changed the treatment landscape of multiple myeloma (MM). CAR T cells and T-cell-redirecting bispecific antibodies (BsAbs) yield impressive responses and extend survival in patients with relapsed/refractory MM. There are now 2 BCM... ...
